Know What's Happening in Healthcare
Know What's Happening in Healthcare
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
CMS lifts Medicare Advantage payments by $13 billion for 2027
The Centers for Medicare & Medicaid Services released the CY 2027 Medicare Advantage and Part D rate announcement on April 6, 2026, confirming a 2.48% net average payment increase—about $13 billion more than 2026. The rule also drops unlinked chart‑review diagnoses from risk scores and ends risk‑adjustment credits for audio‑only telehealth visits.
Also developing:
By the numbers: Gilead to acquire Tubulis for $5B
The U.S. Food and Drug Administration has issued a recall of more than 3 million eye‑drop bottles after sterility concerns were identified. The products, manufactured by K.C. Pharmaceuticals in Pomona, California, span eight categories and are sold under a wide range of store‑brand names at major retailers. No serious illnesses have been linked to the current recall, but the move revives memories of a 2023 eye‑drop outbreak that caused deaths and vision loss.
The University of Arizona’s R. Ken Coit College of Pharmacy is launching a double‑blind, randomized Phase 3 clinical trial to test low‑dose rapamycin’s ability to boost resilience and immune function in adults aged 65 and older. The six‑year study, funded by a $12 million...
HexemBio announced a $10.4 million seed round led by Draper Associates to develop a blood‑stem‑cell rejuvenation therapy built on its Synthetic Human Yolk Sac platform. The technology temporarily places a patient’s own haematopoietic cells into a recreated embryonic niche, then returns...
President Donald Trump unveiled a FY2027 discretionary budget that trims $73 billion from domestic programs, including a $5 billion reduction to the National Institutes of Health and a 55% cut to the National Science Foundation. The plan reshapes federal research, health tech...
Medline (Nasdaq: MDLN) has launched Pick Pack Pro™, an automated fulfillment system at its Montgomery, N.Y., distribution center. The technology combines robotics, conveyor sortation and right‑size packaging to handle high‑volume, narrow‑catalog orders for health plan members. By optimizing order batching...
EQT Life Sciences has exited its minority stake in Tubulis, the German clinical‑stage biotech developing next‑generation antibody‑drug conjugates, selling the position to Gilead Sciences. The transaction adds a promising ADC platform to Gilead’s oncology portfolio. In a separate deal, private‑equity...
Cell and gene therapy is transitioning from ex vivo manufacturing toward in vivo delivery, driven by advances in vector engineering and lipid‑nanoparticle platforms. Major pharma players have launched billion‑dollar acquisitions to secure in vivo CAR‑T and RNA technologies, while the stem‑cell market is...
Late‑stage cell‑replacement trials are expected to read out within the next few years, bringing a functional cure for type 1 diabetes into view. Researchers cite stem‑cell transplants and immune‑shielding strategies as the next frontier, while patients and advocates stress the life‑changing...
Manasi Salgaonkar highlights that class of trade (CoT) research is essential for precise pharmaceutical pricing, contract eligibility, and regulatory compliance. Accurate CoT classification links dispensing settings—retail, hospital, specialty, mail‑order, and IDNs—to specific pricing tiers and rebate agreements. Continuous updates are...
Stipple, a new biotech focused on oncology, announced a $100 million Series A financing round to pursue novel, historically undruggable cancer targets. The round was led by top‑tier venture firms and includes strategic commitments from several large pharmaceutical partners. Stipple’s founding team...
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that alleviate inflammatory and neuropathic pain in rodent studies and are slated for IND‑enabling toxicology this year, aiming for Phase I trials in 2027. Parallel research highlights chronic inflammation’s role...
Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that show potent analgesic effects with minimal off‑target activity. New research links chronic inflammation in the bone‑marrow niche to epigenetic reprogramming of hematopoietic stem cells, suggesting early‑intervention strategies for leukemia prevention. Infinimmune...
Suzhou Spring‑Sea Bio‑Pharmaceuticals announced the discovery of a novel series of glucagon‑like peptide‑1 receptor (GLP‑1R) agonists that demonstrate high potency and prolonged half‑life in pre‑clinical models. The compounds show superior glucose‑lowering efficacy compared with existing market leaders and exhibit favorable...
Researchers at Jiangsu and Shanghai Hengrui have patented Nav1.8 blockers that deliver strong analgesic effects while sparing off‑target channels, opening a new avenue for chronic pain therapy. Parallel studies reveal that chronic inflammation can reprogram hematopoietic stem cells, driving early...
Vertex Pharmaceuticals has filed a patent covering a new series of orexin OX2‑receptor agonists, marking the company’s first public foray into sleep‑modulating therapeutics. The disclosed molecules feature distinct heterocyclic cores and enhanced blood‑brain barrier penetration, aiming for improved potency and...
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that demonstrate potent analgesic effects with minimal off‑target activity, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes the bone‑marrow microenvironment, driving hematopoietic...
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that relieve neuropathic and inflammatory pain in rodents without impairing motor function, with filings in China and the United States and IND‑enabling work slated for later this year....
Biopharma X unveiled a next‑generation anti‑CD30 antibody‑drug conjugate that demonstrated superior efficacy and tolerability compared with the established therapy brentuximab vedotin. In preclinical models, the ADC achieved deeper tumor regressions and a broader therapeutic window, driven by an optimized linker...
Researchers have identified a novel Nrf2 activator that mitigates key pathological features of atopic dermatitis in preclinical studies. The compound suppresses oxidative stress and downregulates pro‑inflammatory cytokines, leading to restored skin barrier integrity in murine models. Data presented at the...
Researchers have identified a new class of liver receptor homolog‑1 (LRH‑1) antagonists that demonstrate potent antitumor activity in preclinical prostate cancer models. In mouse xenografts, oral administration of the compounds reduced tumor volume by up to 65% without notable adverse...
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver potent analgesic effects with minimal off‑target activity, opening a new avenue for chronic pain therapy. Parallel studies highlight how chronic inflammatory signals remodel hematopoietic stem cells,...
As a medical school professor, the protein recommendation I was taught -- 0.8 g/kg body weight -- is actively harming older adults. New data proves it. A 2025 Frontiers in Nutrition trial randomized 126 elderly women with sarcopenia into two groups...
University of Arizona’s R. Ken Coit College of Pharmacy is launching a double‑blind, randomized Phase 3 clinical trial to test low‑dose rapamycin’s ability to improve resilience and immune function in adults 65 and older. The $12 million study is fully funded by...
Sanofi reported mixed Phase 2 results for its bispecific antibody lunsekig. The drug achieved its primary and key secondary endpoints in moderate‑to‑severe asthma and chronic rhinitis with nasal polyps, showing reduced exacerbations, improved lung function and smaller polyps. Conversely, lunsekig failed...
Biogen has signed a collaboration and license agreement with Alloy Therapeutics to use the company’s AntiClastic antisense oligonucleotide (ASO) platform on multiple undisclosed targets. The deal provides Alloy with an upfront cash payment, additional milestone fees and tiered royalties on...
On 1 April, NHS England launched the TPPSFS programme, a £250 million (£320 million) initiative that subsumes the existing Digital Transformation of Screening project and aims to overhaul patient, public and staff‑facing services. The plan outlines eight priority areas, including a full...
Gilead Sciences announced it will acquire Germany‑based Tubulis GmbH for up to $5 billion, adding the biotech’s antibody‑drug conjugate (ADC) platform to its portfolio. The deal follows Gilead’s recent $7.8 billion purchase of Arcellx and a $2 billion acquisition of Ouro Medicines, reflecting...
Gilead announced its third acquisition of 2026, agreeing to pay $3.15 billion upfront for Tubulis, a German startup that has built a next‑generation antibody‑drug conjugate (ADC) platform. The deal includes a contingent earn‑out of up to $1.85 billion tied to future milestones....
Kry Livi has teamed up with HA | Wisdom Wellbeing to embed its fast‑access digital GP service into the provider’s Employee Assistance Programme, extending coverage to more than 16 million people across the UK and Ireland and over 90,000 organisations. Users...
Mobilization of Visceral Adipose Tissue Related to the Improvement in Insulin Sensitivity in Response to Physical Training in NIDDM: Effects of branched-chain amino acid supplements 🔘"Patients who exercised increased their VO2 peak by 41% and their insulin sensitivity by 46%... 🔘with a...
As a medical school professor, I can tell you the most dangerous disease you have never heard of is sarcopenia -- and a massive new meta-analysis just proved it. A 2026 Frontiers in Nutrition review of thousands of community-dwelling older adults...
Sleep Cycle, the AI‑powered sleep‑tracking app, announced that more than 150,000 users have pre‑registered for its upcoming AI‑driven sleep apnea risk detection tool. The sign‑ups, mainly from the United States and United Kingdom, skew toward adults over 45, a group...
Every medical specialty will transform differently due to the technological revolution. In certain fields, such as nursing, psychiatry, obstetrics and gynecology, innovation will have much less impact than on dentistry, cardiology or pathology. In this e-book, we specify in detail how...
A cross‑sectional study of 4,042 German adults found that fewer daily social contacts are linked to higher loneliness, a relationship that holds for both healthy and depressed participants. The association is markedly stronger among the 1,221 respondents with a lifetime...
A California man pleaded guilty to submitting nearly $270 million in fraudulent Medi‑Cal claims over an 11‑month period, billing the state for expensive prescription drugs that were either unnecessary or never dispensed. The scheme leveraged a temporary suspension of prior‑authorization requirements,...
Conferences are emerging as critical growth engines for medical businesses, offering intensive networking, brand visibility, and real‑time market intelligence. Attending just three well‑chosen events annually can expand a provider’s contact list by roughly 30 % and boost referral rates. The global...
Warrington Innovation Network’s Primary Care Network is deploying Aide Health’s AI‑driven platform across six GP surgeries, reaching roughly 55,000 patients. The service delivers daily, short‑form check‑ins to help people with COPD, obesity and hypertension manage medication, monitor symptoms and receive...
1/GLP-1 obesity and weight-loss drugs - such as $NVO Ozempic & Wegovy and $LLY Zepbound & Mounjaro have long become a household name - making Obesity the fastest growing market in the BioTech and Pharma ecosystem and generating unprecedented revenues....
Spent last year deep in supply chain security for my book—pharma near the top of the list for policymakers globally. Excited to dig into Trump's latest tariff announcement with @TomBollyky, one of the leading voices on trade, security, and public...
Weight‑loss drugs targeting the GLP‑1 pathway are reshaping consumer demand for smaller, nutrient‑dense portions, prompting food manufacturers to explore “GLP‑1 friendly” labeling. In the EU, such phrasing is classified as a health claim and, without an approved application, is unlikely...
Computation, Chemistry & Culture for Drug Discovery: Nimbus Therapeutics CEO Abbas Kazimi is the latest guest on The Long Run. Sponsored by @AlphaSenseInc and Dash Bio. https://t.co/XCysW6El1o
Meet X7: The Humanoid #Robot Helping Dispense Medicines in Hospitals by @CyberRobooo #Robotics #MachineLearning #ArtificialIntelligence #Innovation #Technology #AI #ML https://t.co/XwQfzq5NNf
NHS England reports steady progress toward a digital‑by‑default NHS, with most trusts now running electronic patient records (EPRs) and central data repositories. High‑performing trusts are 8% more productive per pound, achieve a 4% shorter length of stay, and meet referral...
"The 4-month intervention with this MDF was effective in reducing IHTC in patients with NAFLD by an absolute reduction of −5.89% and a relative reduction of −24.30% after adjusting for weight loss. Such effect was partly mediated by altered composition...
Musgrove Park Hospital in Somerset has reopened its Nuclear Medicine department after a comprehensive refurbishment that includes a brand‑new SPECT/CT scanner. The state‑of‑the‑art equipment merges nuclear imaging with diagnostic‑quality CT, delivering high‑resolution 3‑D images for precise diagnosis and treatment planning....
A new AI software that essentially fills in the blanks between image slices with synthetic images, enables 2x MRI acceleration ! 👇 “Scans of the abdomen that previously took around 23 minutes now are finished within just nine minutes.” 👏...
MIT researchers unveiled BODHI, a “humble” AI framework that forces large language models to explicitly signal uncertainty in clinical diagnoses. The system implements six integrated steps and a two‑pass chain‑of‑thought prompting that separates internal reasoning from the clinician‑facing response. In...
Akeso presented Phase Ib/II data on its cadonilimab combination with anlotinib and docetaxel in patients whose advanced non‑small cell lung cancer (NSCLC) progressed after PD-(L)1 inhibitor therapy. At a median follow‑up of 21.5 months, the regimen achieved a 6‑month progression‑free...
BioNTech announced it will close its Singapore headquarters, a manufacturing site it purchased from Novartis in 2020. The Tuas Biomedical Park facility, which employs roughly 200 staff, will be shuttered as part of a comprehensive operational review. The decision reflects...
In this episode, Bruno Quinney highlights several breakthrough developments in drug discovery: the FDA’s accelerated approval of Avlaya, the first brain‑penetrant biologic for Hunter syndrome; Eli Lilly’s $2 billion acquisition of Centessa Pharmaceuticals to expand its orexin‑based sleep‑wake therapies; Mount Sinai’s AI‑powered...
